We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
In the latest close session, Tilray Brands, Inc. (TLRY - Free Report) was down 5.76% at $6.54. The stock trailed the S&P 500, which registered a daily loss of 1.74%. Meanwhile, the Dow lost 1.01%, and the Nasdaq, a tech-heavy index, lost 2.38%.
The company's stock has dropped by 11.37% in the past month, falling short of the Medical sector's loss of 7.17% and the S&P 500's loss of 4.99%.
Investors will be eagerly watching for the performance of Tilray Brands, Inc. in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on April 1, 2026. The company is predicted to post an EPS of -$0.14, indicating a 86% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $205.93 million, indicating a 10.85% increase compared to the same quarter of the previous year.
TLRY's full-year Zacks Consensus Estimates are calling for earnings of -$0.48 per share and revenue of $869.99 million. These results would represent year-over-year changes of -580% and +5.93%, respectively.
Any recent changes to analyst estimates for Tilray Brands, Inc. should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 14.18% upward. Tilray Brands, Inc. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 162, finds itself in the bottom 34% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors
In the latest close session, Tilray Brands, Inc. (TLRY - Free Report) was down 5.76% at $6.54. The stock trailed the S&P 500, which registered a daily loss of 1.74%. Meanwhile, the Dow lost 1.01%, and the Nasdaq, a tech-heavy index, lost 2.38%.
The company's stock has dropped by 11.37% in the past month, falling short of the Medical sector's loss of 7.17% and the S&P 500's loss of 4.99%.
Investors will be eagerly watching for the performance of Tilray Brands, Inc. in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on April 1, 2026. The company is predicted to post an EPS of -$0.14, indicating a 86% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $205.93 million, indicating a 10.85% increase compared to the same quarter of the previous year.
TLRY's full-year Zacks Consensus Estimates are calling for earnings of -$0.48 per share and revenue of $869.99 million. These results would represent year-over-year changes of -580% and +5.93%, respectively.
Any recent changes to analyst estimates for Tilray Brands, Inc. should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 14.18% upward. Tilray Brands, Inc. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 162, finds itself in the bottom 34% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.